K4 Elite logo K4 Elite
Home / Peptide Library / Adipotide
Limited Research

Adipotide

GLP & Metabolic · ['FTPP', 'Prohibitin-targeting peptide', 'CKGGRAKDC-GG-D(KLAKLAK)2']

Adipotide is an experimental pro-apoptotic peptide-conjugate designed to target the vasculature of white adipose tissue, studied in preclinical animal models only.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C111H206N36O28S2
Molecular Weight
2557.2 g/mol
PubChem
CID 163360068 ↗
Research Level
Limited Research
Browse the store →
Adipotide chemical structure

Adipotide (also referred to as a prohibitin-targeting peptide or FTPP) is an experimental peptide-conjugate composed of a homing sequence (CKGGRAKDC) that binds a marker associated with the vasculature of white adipose tissue, fused to a pro-apoptotic peptide domain, D(KLAKLAK)2 [1].

The compound has been studied in preclinical animal models, including rodents and non-human primates, as a tool for investigating adipose-tissue vascular biology [1][2]. There is limited published research and no established clinical program at the time of writing.

Adipotide is described in the literature strictly as an experimental research peptide. It has not been evaluated for general use.

The homing portion of adipotide is reported to bind prohibitin, a protein marker associated with the endothelium of white adipose tissue vasculature. Upon internalization, the attached D(KLAKLAK)2 domain is described as disrupting mitochondrial membranes and triggering apoptosis in the targeted endothelial cells [1].

In the published animal studies this vascular-targeting mechanism was associated with reductions in white adipose tissue mass. All such effects are reported here as findings from cited preclinical studies and not as outcomes for any individual.

  • Prohibitin-targeted vascular homing to white adipose tissue [1]
  • Pro-apoptotic (D(KLAKLAK)2) peptide domain mechanism in targeted endothelium [1]
  • Body-composition and adipose-mass endpoints in rodent models [1]
  • Metabolic parameters in obese non-human primate studies [2]
  • Renal safety and reversibility observations noted in preclinical primate work [2]
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Non-human primate study: In a preclinical study, obese rhesus monkeys treated with the prohibitin-targeting peptide over a defined dosing period showed reductions in body weight and adipose mass, with the authors reporting associated metabolic changes and monitoring of renal parameters; effects were described as at least partly reversible [2]. Reported here for scientific reference only.

Rodent tumor-vasculature and adipose studies: Foundational work characterized the homing peptide's binding to prohibitin in adipose vasculature and demonstrated adipose-mass reduction in mouse models following administration of the conjugate [1].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Pro-apoptotic peptide conjugatesCompatible
Same D(KLAKLAK)2 effector domain used in related targeted-peptide research.
Anti-angiogenic agentsNeutral
Both act on vasculature; studied in distinct experimental contexts.
Nephrotoxic compoundsCaution
Renal parameters were monitored in preclinical studies; relevant to study interpretation.
GLP-1 receptor agonistsNeutral
Entirely distinct mechanism; compared only in the broad metabolic literature.
  1. Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004
  2. Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss in obese monkeys. Sci Transl Med. 2011
  3. PubChem CID 163360068 — Adipotide
What is adipotide designed to target?
Published research describes a homing peptide that binds prohibitin on white adipose tissue vasculature, linked to a pro-apoptotic domain [1].
Has adipotide been studied in humans?
The cited literature describes preclinical studies in rodents and non-human primates; there is limited published research and no established clinical program at the time of writing [1][2].
What did the primate study report?
Obese rhesus monkeys showed reductions in body weight and adipose mass with monitoring of renal parameters, reported as at least partly reversible [2].
Is adipotide an approved treatment?
No. It is described strictly as an experimental research peptide [1].
Is this product for human use?
No. It is offered for laboratory research use only and is not intended for human or veterinary use, nor to diagnose, treat, cure, or prevent any disease.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.